echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Frontiers in Neurology: New model can accurately predict early Parkinson's disease

    Frontiers in Neurology: New model can accurately predict early Parkinson's disease

    • Last Update: 2020-05-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    May 11, 2020 /PRNewswire/---How do you smell? Do you find yourself dozing off during the day or dreaming at night? Often, early Parkinson's disease is not associated with typical motor disorder symptoms, thus presenting challenges for early diagnosisNow, neuroscientists at the University of York have developed five different models that use non-kinetic clinical and biological indicators to more accurately predict early Parkinson's diseasetheir five-pattern analysis was one of the first to use non-motor clinical and biological variablesAccording to the study, published in the journal Frontiersin Neurology, these models may help to make diagnosis and interventional treatment more timelyThis new approach is a less invasive alternative than traditional radiotracor scans (DaTscan), which are commonly used to assess a patient's symptoms(photo source:the study's lead author, Charles Leger, an associate professor in the Department of Psychology at the University of York, hopes the model will be used to predict patients with no obvious symptoms of Parkinson's disease in the early stages of the disease"There is no cure for Parkinson's disease, " said De Souza, author of thearticleAll we know now is signs and symptoms, and it can only be treatedTherefore, these models are useful for distinguishing between patients with suspected illness and those who actually get sickDeSouza believes that easier and more accurate early Parkinson's disease predictions can lead to early action, such as regular physical activity, in patients who receive accurate diagnosis to improve activity and balanceresearchers used cross-sectional baseline data from the Parkinson's Progressive Marker Program (PPMI)The PPMI data used are limited to non-sporting clinical variables (e.g., smell, daytime drowsiness, rapid eye movement disorders, age, etc.) and biological variables (e.g., cerebrospinal fluid alpha-synaptic nucleoproteins, tau proteins, beta-amyloid proteins, etc.)(BioValleyBioon.com)Source:' Predictmodelscanscanmoremorepreodetecti-stageParkinson's
    original origin: Charles Legeretal, Non-Motor Clinicaland BioPredictmarkers EnableHighCross-EdAccuracyDetectOfDetectP Frontiersin Neurology (2020) DOI: 10.3389/fneur.2020.00364
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.